Literature DB >> 30733185

Role of Biomarkers in Prediction of Response to Therapeutics in Metastatic Renal-Cell Carcinoma.

Jacob J Adashek1, Meghan M Salgia2, Edwin M Posadas3, Robert A Figlin3, Jun Gong4.   

Abstract

Renal-cell carcinoma remains one of the elusive cancers that lacks a biomarker. It is the eighth most commonly diagnosed malignancy in the United States, and the incidence has slowly trended upward. In addition to the increase in newly diagnosed cases, the prevalence and overall survival of individuals with kidney cancer also has increased substantially. This formal review synopsizes the literature regarding the current treatment landscape, the utility of biomarkers in renal-cell carcinoma, and future directions regarding next-generation sequencing of circulating tumor DNA.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  IOs; VEGF; VHL; ctDNA; mTOR

Mesh：

Substances：

Year:  2019        PMID： 30733185     DOI： 10.1016/j.clgc.2019.01.004

Source DB:  PubMed          Journal:  Clin Genitourin Cancer        ISSN： 1558-7673            Impact factor:   2.872


  11 in total

Review 1.  First-line Immune Checkpoint Inhibitor Combinations in Metastatic Renal Cell Carcinoma: Where Are We Going, Where Have We Been?

Authors:  Jacob J Adashek; Joshua J Breunig; Edwin Posadas; Neil A Bhowmick; Leigh Ellis; Stephen J Freedland; Hyung Kim; Robert Figlin; Jun Gong
Journal:  Drugs       Date:  2022-02-17       Impact factor: 9.546

2.  The presence of tumour-infiltrating neutrophils is an independent adverse prognostic feature in clear cell renal cell carcinoma.

Authors:  Basile Tessier-Cloutier; David Dw Twa; Mahsa Marzban; Jennifer Kalina; Hye-Jung E Chun; Nils Pavey; Zaidi Tanweer; Ruth L Katz; Julian J Lum; Davide Salina
Journal:  J Pathol Clin Res       Date:  2021-03-04

3.  The construction and analysis of competitive endogenous RNA (ceRNA) networks in metastatic renal cell carcinoma: a study based on The Cancer Genome Atlas.

Authors:  Kai Zhao; Qijie Zhang; Yamin Wang; Jiayi Zhang; Rong Cong; Ninghong Song; Zengjun Wang
Journal:  Transl Androl Urol       Date:  2020-04

Review 4.  The Changing Therapeutic Landscape of Metastatic Renal Cancer.

Authors:  Javier C Angulo; Oleg Shapiro
Journal:  Cancers (Basel)       Date:  2019-08-22       Impact factor: 6.639

5.  Identification of genes of prognostic value in the ccRCC microenvironment from TCGA database.

Authors:  Bangbei Wan; Bo Liu; Yuan Huang; Cai Lv
Journal:  Mol Genet Genomic Med       Date:  2020-02-03       Impact factor: 2.183

6.  Limited utility of qPCR-based detection of tumor-specific circulating mRNAs in whole blood from clear cell renal cell carcinoma patients.

Authors:  Sinisa Simonovic; Christian Hinze; Kai M Schmidt-Ott; Jonas Busch; Monika Jung; Klaus Jung; Anja Rabien
Journal:  BMC Urol       Date:  2020-02-04       Impact factor: 2.264

Review 7.  Individualizing Systemic Therapies in First Line Treatment and beyond for Advanced Renal Cell Carcinoma.

Authors:  Yasir Khan; Timothy D Slattery; Lisa M Pickering
Journal:  Cancers (Basel)       Date:  2020-12-13       Impact factor: 6.639

8.  Artificial intelligence prediction model for overall survival of clear cell renal cell carcinoma based on a 21-gene molecular prognostic score system.

Authors:  Qiliang Peng; Yi Shen; Kai Fu; Zheng Dai; Lu Jin; Dongrong Yang; Jin Zhu
Journal:  Aging (Albany NY)       Date:  2021-03-03       Impact factor: 5.682

9.  Taking a SPOP at renal cell carcinoma - unraveling a novel pathway for Tumor progression in clear cell RCC.

Authors:  Hiren V Patel; Sai K Doppalapudi; Eric A Singer
Journal:  EBioMedicine       Date:  2020-06-05       Impact factor: 8.143

10.  Silencing of the chemokine CXC receptor 4 (CXCR4) hampers cancer progression and increases cisplatin (DDP)-sensitivity in clear cell renal cell carcinoma (ccRCC).

Authors:  Wenguang Wang; Zhilu Gan; Qiang Liu; Shenshen Yan; Rexiti Mulati; Yujie Wang
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.